Alignment of new tuberculosis drug regimens and drug susceptibility testing: A framework for action

The Lancet Infectious Diseases

Volumn 13, Issue 5, 2013, Pages 449-458

  Wells, William A ^a   Boehme, Catharina C ^b   Cobelens, Frank GJ ^c   Daniels, Colleen ^d   Dowdy, David ^e   Gardiner, Elizabeth ^a   Gheuens, Jan ^f   Kim, Peter ^g   Kimerling, Michael E ^f   Kreiswirth, Barry ^h   Lienhardt, Christian ⁱ   Mdluli, Khisi ^a   Pai, Madhukar ^j   Perkins, Mark D ^b   Peter, Trevor ^k   Zignol, Matteo ⁱ   Zumla, Alimuddin ^l,m   Schito, Marco ^g  

^a Global Alliance for TB Drug Development   (United States)

^b FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Treatment Action Group   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j MCGILL UNIVERSITY   (Canada)

^k CLINTON HEALTH ACCESS INITIATIVE   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF ZAMBIA   (Zambia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT;

ALGORITHM; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG RESISTANCE; DRUG SURVEILLANCE PROGRAM; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

ALGORITHMS; ANTITUBERCULAR AGENTS; DATABASES, FACTUAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84876697735     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70025-2     Document Type: Review

References (63)

1. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
2. Introducing new approaches and tools for enhanced TB control (INAT) subgroup Stop TB Partnership, (accessed Nov 23, 2010). http://www.stoptb.org/wg/dots_expansion/inatabout.asp.
3. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010, 375:2100-2109.
4. Wells WA, Konduri N, Chen C, et al. TB regimen change in the high burden countries. Int J Tuberc Lung Dis 2010, 14:1538-1547.
5. Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME Size and usage patterns of private TB drug markets in the high burden countries. PLoS One 2011, 6:e18964.
6. Fox W, Ellard GA, Mitchison DA Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3(suppl 2):S231-S279.
7. Global plan to stop TB 2006-2015. Report No.: WHO/HTM/STB/2006.35 2006, Stop TB Partnership and WHO, World Health Organization, Geneva.
8. New TB regimens: what countries want. The value proposition of existing and new first-line regimens for drug-susceptible tuberculosis 2009, TB Alliance, Global Alliance for TB Drug Development, New York.
9. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update 2011, WHO, World Health Organization, Geneva.
10. Global tuberculosis report 2012 2012, WHO, World Health Organization, Geneva.
11. Grosset JH, Singer TG, Bishai WR New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012, 16:1005-1014.
12. A controlled trial of a 4-month quinolone-containing regimen for the treatment of pulmonary tuberculosis ClinicalTrials.gov, (accessed Feb 12, 2013). http://clinicaltrials.gov/ct2/show/NCT00216385.
13. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB) ClinicalTrials.gov, (accessed Feb 12, 2013). http://clinicaltrials.gov/ct2/show/NCT00864383.
14. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012, 56:3114-3120.
15. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
16. Evaluation of 8 weeks of treatment with the combination of moxifloxacin, PA-824 and pyrazinamide in patients with drug sensitive and multi drug-resistant pulmonary tuberculosis (TB) ClinicalTrials.gov, (accessed Jan 13, 2013). http://clinicaltrials.gov/ct2/show/NCT01498419?term=NCT01498419&rank=1.
17. Diacon AH, Donald PR, Mendel CM Early bactericidal activity of new regimens for tuberculosis-authors' reply. Lancet 2013, 381:112-113.
18. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012, 56:3271-3276.
19. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
20. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
21. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
22. Shin SS, Asencios L, Yagui M, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis 2012, 16:1538-1543.
23. Jacobson KR, Theron D, Kendall EA, et al. Implementation of GenoType MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013, 56:503-508.
24. Barnard M, Warren R, Van Pittius NG, et al. GenoType MTBDRsl line probe assay shortens time to diagnosis of XDR-TB in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012, 186:1298-1305.
25. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs 2008, WHO, World Health Organization, Geneva.
26. Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D Diagnosis of tuberculosis and drug resistance: what can new tools bring us?. Int J Tuberc Lung Dis 2012, 16:860-870.
27. Van Deun A, Martin A, Palomino JC Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010, 14:131-140.
28. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, published online March 24. http://dx.doi.org/10.1016/S1473-3099(13)70008-2.
29. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012, 7:e36966.
30. Evans CA GeneXpert-a game-changer for tuberculosis control?. PLoS Med 2011, 8:e1001064.
31. Pai M, Palamountain KM New tuberculosis technologies: challenges for retooling and scale-up. Int J Tuberc Lung Dis 2012, 16:1281-1290.
32. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how-to'-practical considerations 2011, WHO, World Health Organization, Geneva.
33. Trebucq A, Enarson DA, Chiang CY, et al. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis 2011, 15:1567-1572.
34. Steingart KR, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, 1. CD009593.
35. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 2013, WHO, World Health Organization, Geneva.
36. Moore DA, Shah NS Alternative methods of diagnosing drug resistance-what can they do for me?. J Infect Dis 2011, 204(suppl 4):S1110-S1119.
37. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 2012, 16:812-816.
38. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000146.
39. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012, 7:e39754.
40. de Oliveira MM, da Silva Rocha A, Cardoso Oelemann M, et al. Rapid detection of resistance against rifampicin in isolates of Mycobacterium tuberculosis from Brazilian patients using a reverse-phase hybridization assay. J Microbiol Methods 2003, 53:335-342.
41. Chang KC, Yew WW, Zhang Y Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011, 55:4499-4505.
42. Jureen P, Werngren J, Toro JC, Hoffner S Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008, 52:1852-1854.
43. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, 55:2032-2041.
44. Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012, 90:693-698.
45. Walker TM, Ip CLC, Harrell RH, et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 2013, 13:137-146.
46. Daum LT, Rodriguez JD, Worthy SA, et al. Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J Clin Microbiol 2012, 50:3831-3837.
47. Bozeman L, Burman W, Metchock B, Welch L, Weiner M Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005, 40:386-391.
48. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005, 56:1058-1062.
49. Umubyeyi AN, Rigouts L, Shamputa IC, et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007, 59:1031-1033.
50. Verma JS, Nair D, Rawat D, Manzoor N Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis. Indian J Med Microbiol 2011, 29:280-282.
51. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
52. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N Mathematical models in the evaluation of health programmes. Lancet 2011, 378:515-525.
53. Oxlade O, Falzon D, Menzies D The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. Eur Respir J 2012, 39:626-634.
54. Cohen T, Manjourides J, Hedt-Gauthier B Linking surveillance with action against drug-resistant tuberculosis. Am J Respir Crit Care Med 2012, 186:399-401.
55. Target product profiles Evidence-based tuberculosis diagnosis, (accessed Sept 16, 2012). http://tbevidence.org/resource-center/target-product-profiles/.
56. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 2012, 9:e1001306.
57. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs clinic-based roll-out in South Africa. Trop Med Int Health 2012, 17:1142-1151.
58. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME Which new diagnostics for tuberculosis, and when?. J Infect Dis 2012, 205(suppl 2):S191-S198.
59. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007, 11:485-495.
60. Cuevas LE, Yassin MA, Al-Sonboli N, et al. A multi-country non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis. PLoS Med 2011, 8:e1000443.
61. Lin HH, Langley I, Mwenda R, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis 2011, 15:996-1004.
62. Lin HH, Dowdy D, Dye C, Murray M, Cohen T The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ 2012, 90:739. 47A.
63. Pai M TB diagnostics: top 10 FAQs by test developers (accessed Feb 18, 2013). http://www.tbfaqs.org/.